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Cyclosporine is a potent immunosuppressive agent used to treat a wide range of
canine inflammatory diseases. Unfortunately, optimal dosing protocols for achieving
immunosuppression with cyclosporine in dogs remain unclear, and standard methods that
objectively monitor effectiveness of immunosuppression have not been established. We
evaluated an already established panel of biomarkers of immunosuppression in vivo with
two oral dosages of cyclosporine in seven normal dogs, a high dosage known to induce
immunosuppression and a lower dosage used to treat atopy, with a washout period
between the two dosages. The biomarker panel included the flow cytometric evaluation
of T-lymphocyte cytokine expression (IL-2, IL-4, & IFN-gamma). High dosage
cyclosporine resulted in significant decreases in IL-2 and INF-gamma expression, but not
IL-4 expression. Low dosage cyclosporine was associated with a significant decrease in
INF-gamma expression, while IL-2 expression was not affected. The results
demonstrated suppression of biomarkers in a dose-dependent manner.
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CHAPTER I
INTRODUCTION
Cyclosporine is a potent immunosuppressive agent derived from the fungus
Tolypocladium inflatum, initially discovered by Borel in the Sandoz laboratory, with the
findings of its immunosuppressive effects first described in 1976 at the British Society of
Immunology (1). It is used in both human and veterinary medicine to treat a wide range
of inflammatory and immune-mediated diseases as well as to prevent organ transplant
rejection. In dogs, because of its immunosuppressive, anti-inflammatory, antiproliferative, and lacrimomimetic properties, cyclosporine is used for the treatment of
diseases such as atopy, keratoconjunctivitis sicca, autoimmune skin disorders, perianal
fistula, inflammatory bowel disease, granulomatous meningoenchephalitis, and immunemediated blood disorders such as immune-mediate hemolytic anemia (2-8).
Cyclosporine is also used in canine transplantation (9-11).
Mechanism of Action of Cyclosporine
Cyclosporine is a calcineurin inhibitor, which specifically inhibits T-cell function,
and potently inhibits cell-mediated immunity with a relatively lesser effect on humoral
immunity (12). Cyclosporine initiates its immunosuppressive effects once in T-cells by
binding to intracellular proteins called cyclophilins. The most abundant cyclophilin
found in T cells is cyclophilin A. The binding of cyclosporine to cyclophilin facilitates
the complex’s affinity for calcineurin. When this complex binds to calcineurin, inhibition
1

of calcineurin occurs through inhibition of phosphatase activity, thus preventing
calcineurin’s binding and subsequent activation of the nuclear factor of activated T-cells
(NFAT). Inhibition of NFAT leads to decreased cytokine gene expression, with the most
notable cytokine being IL-2. Other cytokines shown to have decreased expression in
response to cyclosporine include IL-4, INF-γ and TNF-α. The role of IL-2 in the
inflammatory process is complex and multifactorial, involving both pro-inflammatory as
well as regulatory functions. In T-cells, IL-2 recognition by the IL-2 receptor initiates a
signaling cascade which ultimately promotes cytokine transcription, cell survival, cellcycle entry, and proliferation. IL-2 works within T-cells to further induce the expression
of IL-2 receptors. IL-2 is the most effective cytokine for T-cell clonal expansion (13).
By decreasing IL-2 expression in CD4+Th1 cells, proliferation and activation of both Thelper and T-cytotoxic lymphocytes are inhibited and the immune response is blunted.
Current Use of Cyclosporine in Canine Medicine
Cyclosporine is utilized in the treatment of many inflammatory and immunemediated diseases in dogs. In dermatologic applications such as canine atopic dermatitis,
cyclosporine is often started at a low once daily dosage, and used at that dosage until
remission of disease is achieved (14-17). Cyclosporine therapy is then slowly weaned
down until the lowest effective dose to maintain disease remission is found. In more
critical and life-threatening diseases such as immune-mediated hemolytic anemia and
immune-mediated thrombocytopenia, the best way to utilize cyclosporine therapy is not
known. It is often started at a much higher dose than that used to treat canine atopic
dermatitis, often demonstrating multiple possible side effects as well as being cost
prohibitive for medium to large breed dogs. Oral cyclosporine preparations have been
2

shown to have an unpredictable bioavailability, and therapeutic drug monitoring is
therefore recommended for many disease conditions in dogs in order to achieve a target
cyclosporine blood concentration range. Veterinary pharmacology laboratory
recommendations have varied widely regarding the type of assay used to determine
cyclosporine concentrations, the target cyclosporine concentration range for controlling
disease, and whether the target should be based on trough blood concentrations or peak
blood concentrations or both. Strictly relying on blood cyclosporine concentrations
during treatment, however, may not determine if there is sufficient immunosuppression
for disease control.
Cyclosporine target ranges are often empirical and speculative, with the main
criteria for adequacy of treatment being response to therapy and disease control. Target
blood concentrations do not necessarily correlate with clinical outcome or response to
therapy. Many of our canine patients respond to therapy although their blood
concentrations are less than the ideal cyclosporine target range, and some do not respond
even when their cyclosporine blood concentrations are within the recommended
cyclosporine target range. There is currently a lack of a more objective measure for
assessing the immune system during immunosuppressive therapy for predicting adequacy
of treatment.
Project Significance
Recent studies in human medicine utilizing peak drug concentrations for
therapeutic monitoring have had had mixed results, suggesting the optimal
pharmacokinetic monitoring strategy for cyclosporine is still undetermined. Assessing
the biologically relevant effects of the drug, rather than measuring blood concentration,
3

may allow for improved immunosuppressive therapy. Pharmacodynamic monitoring
allows for the assessment of the biological effect of a drug on the immune system and the
degree of immunosuppression achieved. Several pharmacodynamic biomarkers have
been studied in human medicine, including lymphocyte proliferation, enzyme activity
(calcineurin), lymphocyte surface antigens, and intracellular cytokine quantification.
Clear relationships have been shown between pharmacodynamic parameters and drug
concentrations. Furthermore, through pharmacodynamic monitoring, human studies have
shown individually distinct degrees of calcineurin inhibitor sensitivity in patients despite
comparable drug concentrations. A clinical benefit has been demonstrated when
pharmacodynamic monitoring of either calcineurin activity or IL-2 production was
utilized, and these methods show great promise for optimizing cyclosporine therapy as
well as delivering individualized therapy.
Molecular methods have been used in veterinary medicine to objectively measure
cytokines before and after treatment of certain diseases. These methods have not
previously been used to correlate immune suppression at differing cyclosporine dosages
or to validate target cyclosporine blood concentrations. Offering individualized
immunosuppressive therapy for our canine patients based on a better assessment of the
status of the immune system would potentially allow for tighter control of cyclosporine
therapy, and potentially reduce the side effects seen as well as the costs associated with
treatment. Because of the lack of evidence supporting the use of therapeutic drug
monitoring to control disease in veterinary medicine, a more objective means to measure
the effectiveness of cyclosporine therapy is needed. The objectives of our study were to
establish and evaluate a panel of molecular biomarkers of immunosuppression through
4

the use of flow cytometry and then to utilize this panel of molecular biomarkers to
thoroughly evaluate the pharmacodynamics of cyclosporine in the dog. The end goal of
our work was to establish a select panel of biomarkers that could be used to monitor the
immunosuppressive effects of drugs such as cyclosporine and to establish the relationship
between blood concentrations of cyclosporine and measurable immunosuppression.
Preliminary Studies
Initial work in our laboratory used flow cytometry to investigate a panel of
biomarkers published in the human literature which demonstrated suppression of
biomarkers in transplant recipients receiving cyclosporine therapy (18). The biomarker
panel was also chosen based on the availability of antibodies known to be specific to
dogs or those which cross-reacted with canine markers. The biomarker panel included
flow cytometric evaluation of activated T-cell intracellular cytokine expression (IL-2, IL4, & IFN-γ) and T-cell surface antigen expression (CD25 & CD95).
In the initial pilot in vitro study, lymphocytes from 3 healthy dogs were incubated
for different time periods in varying concentrations of activator and cyclosporine at a
concentration of 200 ng/ml. This cyclosporine concentration was chosen because
cyclosporine concentrations higher than this resulted in negligible additional suppression
of mRNA expression during real time RT-PCR in dogs in an already published study in
dogs, and because preliminary studies in our laboratory showed it to be an effective drug
concentration. Cells were prepared according to already published methods and
incubated with CD3 to identify T-cells, and then double stained with antibodies against
the target biomarker. The cells were then assessed by flow cytometry. The CD3 positive
T-cells were evaluated for biomarker expression both at baseline and after activation, and
5

the results helped to establish optimal sample preparation methodology in subsequent
studies. (Figs. 1.1, 1.2, 1.3, and 1.4)

Figure 1
Canine PBMC gated based on their size and granularity, presented as a dot plot
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Figure 2
CD3 expression analyzed using dot plots and single gate statistics
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Figure 3
Two-color analysis for CD3 and IL-2 staining performed using dot
plots with quadrant statistics
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Figure 4
Phorbol 12-myristate 13-acetate (PMA) and ionomycin activated CD3+ T cells
increase expression of IL-2 (red line) compared to their non-activated
counterparts (green line)
This pilot study demonstrated significant cyclosporine-associated reduction in
biomarker expression at 12 hours after exposure to the activators phorbol 12-myristate
13-acetate (PMA)/Ionomycin for intracellular cytokines and 36 hours after exposure to
the activator concanavalin A. IL-2 expression was reduced by 54%, IL-4 by 34%, and
IFN-γ by 81%, and CD25 was reduced by 25% and CD95 by 18%. This confirmed
consistent cyclosporine-induced suppression of the selected biomarkers.
A subsequent larger scale in vitro study was then performed utilizing our already
established sample preparation protocols. Blood was drawn from six healthy dogs, and
peripheral blood mononuclear cells (PBMC) were isolated and activated. Half of the
cells were incubated with a cyclosporine concentration of 200 ng/mL prior to activation,
while the other half was not exposed to cyclosporine. All samples were analyzed using
flow cytometry, and the expression of intracellular cytokines IL-2, IL-4, and IFN-γ was
9

evaluated after 6, 12, and 24 hours of cyclosporine exposure. Each cytokine exhibited a
time-dependent suppression profile, with activated samples exposed to cyclosporine
demonstrating a lower cytokine expression than untreated controls. We also evaluated
the expression of the surface T-cell activation molecules CD25 and CD95 by flow
cytometry after 36 hours of drug exposure. Expression of these surface molecules
decreased significantly when activated in the presence of cyclosporine as compared to
untreated controls. The results from this larger scale in vitro study suggested that
suppressed expression of the markers related to T-cell activation could potentially be
utilized as an indicator of the efficacy of cyclosporine therapy in dogs. (Figs 1.5 and
1.6).
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Figure 5
Increase on activation of MFI of IL-2, IL-4, and IFN-γ for cyclosporine (CsA) treated
activated T-cells relative to untreated controls
Data are analyzed by calculating the percent increase on activation and by comparing the
activated sample MFI values. * indicates a statistically significant difference due to the
effects of cyclosporine (P< 0.05).
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Figure 6
Percent increase in expression on activation (A) and MFI (B) for T-cell surface molecules
CD25 and CD95 after 36 hours of incubation
Data are analyzed by calculating the percent increase on activation and by comparing the
activated sample MFI values. * Indicates a statistically significant difference due to the
effects of cyclosporine (P<0.05).
This provided the evidence needed to move forward with in vivo studies in normal
dogs to further evaluate the pharmacodymanics of cyclosporine in dogs.
In a small pilot in-vivo study, oral cyclosporine was administered to two normal
dogs at standard twice daily immunosuppressive doses for one week, with doses adjusted
based on high performance liquid chromatography (HPLC) measurement of blood
12

cyclosporine concentrations to achieve currently recommended target trough
cyclosporine concentrations for immunosuppression (500 – 600 ng/ml trough
concentrations). Treated animals had a decreased expression of IL-2 (reduced by 51%
and 42%), IL-4 (33% and 26%), and INF-γ (51% and 38%). There were variable results
for the surface expression markers CD25 and CD95, with neither dog showing a
decreased expression of CD25 and only one dog showing decreased expression of CD95.
Due to the variable results and lack of suppression in the pilot in-vivo study, the surface
expression markers CD25 and CD95 were not further analyzed in subsequent studies.
(Figs 1.7 and 1.8).
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Figure 7
IL-2 expression in activated T-cells from 3 dogs, with one dog serving as a control dog
and the other two dogs being dosed at standard twice daily immunosuppressive
doses of cyclosporine
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Figure 8
CD25 and CD95 expression in activated T-cells from 3 dogs, with one dog serving
as a control dog and the other two dogs being dosed at standard twice daily
immunosuppressive dosages of cyclosporine
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CHAPTER II
LITERATURE REVIEW
Cyclosporine is a potent immunosuppressive drug with treatment applications in
both human and veterinary medicine for autoimmune diseases and organ transplantation.
It is currently being applied to a spectrum of inflammatory and immune-mediated
diseases in dogs. It is a cyclic polypeptide derived from the soil fungus Tolypocladium
inflatum. Cyclosporine was discovered in the Sandoz laboratory by Borel in Switzerland
in the 1970s, demonstrating in vitro inhibition of human immune reactions as well as
prolonging survival of skin grafts (1-3). This data was presented in 1976 at the British
Society of Immunology, paving the pathway towards its use as an immunosuppressive
agent for organ transplantation (1,2). Experiments then pursued initially in rats which
showed prolonged survival of heart allografts and then later in dogs which showed
prolonged survival of renal allografts (1). Cyclosporine A was first described in human
medicine by Calne in 1978 to prevent organ rejection in patients receiving renal allografts
(2,3). Once these results were shown to be repeatable, cyclosporine became and still
remains a cornerstone of immunosuppression in human organ transplant medicine (4,5).
Cyclosporine was approved by the U.S. Food and Drug Administration in 1983 for the
treatment and prevention of transplant rejection in human medicine (4). Novartis Animal
Health received FDA approval in 2003 for oral cyclosporine capsules marketed as
Atopica® for the treatment of atopic dermatitis in dogs.
18

Oral Cyclosporine Formulations
Two oral formulations of cyclosporine exist. The initial formulation of
cyclosporine was a vegetable-oil based preparation called Sandimmune®.
Sandimmune® demonstrates significant variation in absorption from patient to patient,
having wide intra-individual and inter-individual differences in pharmacokinetics.
Because of this, a newer formulation was introduced into the human market by Novartis
in 1996. The newer formulation is an ultramicronised formulation which forms a
microemulsion upon contact with aqueous fluids and has a much more consistent and
predictable absorption (6). The ultramicronised formulation is estimated to have as much
as 50% better absorption than Sandimmune, with lower intra-individual variability.
Novartis manufactures the approved human ultramicronised formulation product
(Neoral®) as well as the veterinary approved ultramicronised formulation product
(Atopica®). There are also generic formulations available, both as the ultramicronised
formulation and the non-ultramicronised formulation. The generic ultramicronised
formulations demonstrate equivalent product bioavailability as the FDA approved
product, but only the FDA approved veterinary product (Atopica®) has undergone
extensive pharmacokinetic testing in dogs to demonstrate its clinical utility and therefore
the recommended product. Because of the poor absorption and extreme variability of the
non-ultramicronised Sandimmune® preparation, it is not recommended in dogs.
Mechanism of Action
With antigenic stimulation (either endogenous or exogenous) comes antigen
presentation and initial cell surface signaling to T-lymphocytes. This signaling begins a
cascade of cellular events, starting with antigen binding to CD3 receptors on the surface
19

of T-lymphocytes. This interaction causes an increase in intracellular calcium and the
activation of calcineurin. Activated calcineurin then dephosphorylates inactive nuclear
factors of activation of T-cells (NFAT), leading to NFAT translocation into the nucleus
and the intra-nuclear transcriptional gene upregulation of several important cytokines
including IL-2, IL-4, TNF-α, and INF-γ (4,7,8). IL-2 production plays a key role in the
activation and proliferation of T-lymphocytes. IL-2 receptors on T lymphocytes are
composed of three trans-membrane proteins consisting of α (CD-35), β (CD122), and γ
(CD132). Once the IL-2 receptors are stimulated, they initiate a feed forward mechanism
accelerating the immune response (9). Both Th1 and Th2 cells demonstrate increased
proliferation in response to IL-2.
Cyclosporine is a calcineurin inhibitor, thereby modulating the adaptive immune
system and specifically inhibiting T-cell function, potently inhibiting cell-mediated
immunity with a relatively less effect on humoral immunity (10,11). Calcineurin
inhibitors such as cyclosporine begin their biological effects by binding intracellular
proteins called cyclophilins. The most abundant cyclophilin found in T lymphocytes is
cyclophilin A. The binding of cyclosporine to cyclophilin A facilitates the complex’s
affinity for calcineurin. When this complex binds to calcineurin, inhibition of calcineurin
occurs by inhibiting its phosphatase activity, thus preventing its binding and the
subsequent activation of NFAT (4). This leads to decreased cytokine gene expression,
with the most notable cytokine being IL-2. Other cytokines shown to have decreased
expression in response to exposure to cyclosporine include IL-4, INF-γ, and TNF-α. By
decreasing IL-2 expression in CD4+ Th1 cells, proliferation and activation of both T
helper and T-cytotoxic lymphocytes are inhibited and the immune response is blunted.
20

Pharmacokinetics
Absorption
With oral dosing of cyclosporine, absorption occurs through the gut epithelium in
the small intestine. The Sandimmune® formulation has an extremely variable absorption
profile, being dependent on factors such as bile flow and the presence or absence of food
and gastrointestinal motility (12). The newer ultramicronised formulation does not
depend on biliary action nor enzymes or small intestinal secretions for absorption,
leading to a much more consistent and predictable absorption (12). The ultramicronised
formulation is estimated to have up to as much as 50% better absorption than
Sandimmune, with lower intra-individual variability. In dogs dosed with Atopica®,
bioavailability is, however, still variable and can range from 23 to 45 percent (13).
One study demonstrated a 22 percent decrease in bioavailability as well as an
increase in variability of individual blood concentrations when oral Atopica® was given
to dogs with food, and recommendations were made to administer Atopica® two hours
before or after feeding (14). A subsequent study evaluated the clinical response in dogs
with canine atopic dermatitis treated with Atopica®, to determine whether dosing with
food or not made a difference. In this study, there was not a significant difference in
clinical efficacy between dogs receiving cyclosporine with food compared to those that
did not receive cyclosporine with food (15).
P-glycoprotein is a transporter protein located within the brush border of the
enterocytes within the gut epithelium which is able to pump a wide variety of xenobiotics
out of the cell and back in to the gut lumen. Cyclosporine is one drug that is transported
by P-glycoprotein. A recent study of six dogs (three normal dogs and three dogs with P21

glycoprotein deficiency) did not show a difference in cyclosporine pharmacokinetics
when administered orally as well as intravenously, suggesting that intestinal Pglycoprotein levels do not significantly affect intestinal absorption of cyclosporine in
dogs (16). This differs from studies in human medicine, where intestinal P-glycoprotein
levels were shown to play a significant role in first-pass metabolism, presumably being a
rate-limiting step in absorption (17).
In one study, cimetidine, an H2-receptor antagonist, given concurrently with oral
cyclosporine (Neoral®), caused a significantly longer time until maximal blood
cyclosporine concentrations in healthy dogs as compared to those dogs not receiving
cimetidine (18). In dogs concurrently treated with cimetidine, there was not however a
concurrent increase in the overall maximum concentration of cyclosporine. This
suggested a cimetidine-associated altered and prolonged absorption of cyclosporine from
the gastrointestinal tract.
Distribution
Cyclosporine has an increased binding affinity for red blood cells as well as
plasma lipoproteins. Once in systemic circulation, cyclosporine distributes widely,
accumulating in the skin, liver, kidneys, and fat of dogs (12). Tissue levels exceed levels
in serum by a factor of 3 to 14 (12). Peak blood concentration times are variable, but
usually occur around 2 hours after oral administration of Atopica® (14,19). Blood levels
then fade away over the dosing interval.
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Metabolism
Cyclosporine is extensively metabolized by hydroxylation and/or Ndemethylation, with many different metabolites being produced (20). Metabolism occurs
in the liver, small intestine, and kidneys, with the liver being the major site of
metabolism. In dogs, hepatic metabolism is extensive and occurs quickly, with 70 to
100% of the drug being metabolized within 30 minutes in one study (12,20). In the liver,
the P-450 3A microsomal enzymes serve as the key pathway of metabolism. The
microsomal enzymes in the small intestine are much more variable and slower in their
metabolism of cyclosporine. In one study, the small intestine metabolized approximately
34% of what was metabolized by the liver (20). The major metabolites produced by the
liver in dogs include the 9 γ-hydroxylated cyclosporine metabolite, 4 N-desmethylated
metabolite, 1-β-(8΄) hydroxylated metabolite, and 1-β-1-ε-cyclized metabolite (20).
Drugs known to decrease the metabolism of cyclosporine in humans by inhibiting
the hepatic P-450 enzyme system, leading to increased cyclosporine blood
concentrations, include allopurinol, amiodarone, colchicine, bromocriptine, calcium
channel blockers (such as diltiazem), cimetidine, cisapride, danazol, digoxin,
doxycycline, erythromycin, fluconazole, flavonoids in grapefruit juice, ketoconazole,
itraconazole, metoclopramide, omeprazole, sertraline, verapamil, and high dose
methylprednisolone (12, 13, 21). Drugs known to decrease blood concentrations of
cyclosporine in humans through either induction of enzymes involved in the metabolism
or increased excretion of cyclosporine include ciprofloxacin, nafcillin, rifampin,
phenobarbital, phenytoin, terbinafine, and trimethoprim-sulphadimidine (13).
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In dogs, drugs given concurrently with cyclosporine to decrease cyclosporine
dosages include ketoconazole and fluconazole. Ketoconazole decreases oral cyclosporine
requirements by as much as 75 percent, depending on the dose of ketoconazole
administered (22). Fluconazole has been shown to significantly reduce the oral
cyclosporine dosage needed to maintain target trough concentrations by between 30 to
50% (23,24). With concurrent fluconazole and cyclosporine, significant increases in
cyclosporine blood concentrations are seen, suggesting that adjusted doses may be
necessary when dogs are treated with both drugs (24). High dose powdered whole
grapefruit has been shown to increase the cyclosporine blood concentration in dogs and
has the potential to reduce orally administered cyclosporine requirements, through the
proposed mechanism of furanocoumarins in grapefruit juice inhibiting P-450 3A
microsomal intestinal enzymes. In one study with experimentally induced diabetes in
dogs, there was an accelerated metabolic clearance of cyclosporine under hyperglycemic
conditions.
Excretion
Most cyclosporine metabolites are excreted through the biliary system, with
minimal renal excretion (13).
Adverse Effects
Many adverse effects are associated with cyclosporine therapy in dogs. In a
multisite, placebo-controlled field study safety analysis, 265 dogs were administered
either placebo or Atopica® at a dosage of 5 mg/kg/day, with treated dogs receiving
Atopica® for a total of 4 months. The following were the most common side effects seen
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in dogs receiving Atopica®: vomiting (30.9%), diarrhea (20.0%), persistent otitis externa
(6.8%), urinary tract infections (3.8%), anorexia (3.0%), lethargy (2.3%), gingival
hyperplasia (2.3%), and lymphadenopathy (2.3%). Other less common clinical signs
noticed included constipation, flatulence, Clostridial organisms in the feces, nausea,
regurgitation, polyuria/ploydipsia, strong urine odor, proteinuria, pruritus,
erythema/flushed appearance, pyoderma, sebaceous adenitis, crusty dermatitis, excessive
shedding, coarse coat, alopecia, papillomas, histiocytoma, granulomatous masses or
lesions, cutaneous cysts, epulis, benign epithelial tumors, multiple hemangiomas, raised
nodules on pinnae, seizures, shaking/trembling, hind limb twitching, panting, depression,
irritability, hyperactivity, becoming quieter, increased light sensitivity, reluctance to go
outside, weight loss, and hepatitis. The most common clinicopathology changes noticed
during Atopica® therapy included an elevated creatinine (7.8%), hyperglobulinemia
(6.4%), hyperphosphatemia (5.3%), hyperproteinemia (3.4%), hypercholesterolemia
(2.6%), hypoalbuminemia (2.3%), hypocalcemia (2.3%), and an elevated BUN (2.3%).
Other clinicopathological changes were less common, and included hypernatremia,
hyperkalemia, elevated ALT, elevated ALP, hypercalcemia, and hyperchloremia.
In other studies published throughout the literature, the most notable adverse
effects of cyclosporine are gastrointestinal in nature, including diarrhea, vomiting/nausea,
and anorexia (25). These side effects are seen across a range of dosages, with an
increased incidence seen at higher dosages (25). Dermatological side effects include
hirsutism, coat shedding, gingival hyperplasia, gingival eruption cysts in neonatal dogs,
cutaneous papillomatosis hyperplasia, hyperkeratosis of footpads, psoriasiform-lichenoidlike dermatitis, and lymphoplasmatoid dermatitis (26-30). Clinicopathological
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abnormalities seen in conjunction with cyclosporine therapy which were not reported in
the field study safety analysis include lymphopenia, eosinopenia, transient thrombosis,
anemia, and leukocytosis (25). Concurrent infections have been documented to occur
during cyclosporine therapy, including acute toxoplasmosis, bacterial respiratory
infection, bacterial urinary infection, purulent pericarditis, Neospora caninum central
nervous system infection, demodicosis, pyoderma, pyelonephritis, pyometra, and septic
arthritis (28, 31, 32). Other adverse cyclosporine reactions reported in the literature
include hepatotoxicity, defective hepatic protein synthesis, inhibition of insulin release,
lameness, lethargy, nephropathy, increase in peripheral insulin resistance, transient
hypoalbuminemia, anaphylactic reaction, tremors, angioedema, emergence of neoplasia,
and cyctic nodules of unknown etiology located in the pericardium and diaphragm (6,33).
Recent findings have also suggested cyclosporine may increase platelet procoagulant
activity in dogs (34). In a single experimental study in dogs evaluating the effects of
cyclosporine on blood pressure, results indicated that cyclosporine increased blood
pressure through activation of the renin-angiotensin-aldosterone system (35).
Precautions
The safety and efficacy of cyclosporine has not been evaluated in dogs less than 6
months of age or in dogs less than 4 pounds in weight, and the drug should therefore not
be used or be used cautiously in these patients. Because of the dampened immune system
associated with cyclosporine therapy, vaccine efficacy may be impacted. Modified live
vaccines are not recommended with concurrent cyclosporine therapy because of the
potential for reactivation of the pathogen (13, 36). Cyclosporine is not for use in
breeding, pregnant, or lactating dogs. Malignancies, including lymphoma, have occurred
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in conjunction with concurrent use of cyclosporine, and it is therefore contraindicated in
dogs with a history of neoplasia. Nephrotoxicity and renal dysfunction have rarely been
reported in the veterinary literature, although renal disease is a common adverse effect in
people during cyclosporine therapy. Nephrotoxicity has not been reported in dogs
receiving therapeutic dosages, but has occurred with prolonged significantly increased
serum blood drug concentrations (> 3000 ng/ml) (6).
Measurement of Cyclosporine Blood Levels
The assay used to measure cyclosporine blood levels as well as the sample type
must be considered when interpreting results. Plasma values will be lower than wholeblood values due to the concentration of cyclosporine in erythrocytes and leukocytes.
While either whole blood or plasma cyclosporine concentrations can be measured, most
laboratories recommend measuring whole blood concentrations. Cyclosporine
concentrations can be measured by high-pressure liquid chromatography (HPLC),
fluorescence polarization immunoassay (TDx method), and specific monoclonal antibody
radioimmunoassay (RIA) methods. HPLC measures only the parent drug, and does not
measure cyclosporine metabolites. Both TDx and RIA methods measure parent drug as
well as metabolites, and blood cyclosporine concentrations will therefore be higher
compared to the same sample analyzed using HPLC. Although HPLC is labor intensive
and not routinely offered for patient monitoring, it is considered the gold standard for
measuring cyclosporine blood concentrations. TDx and RIA are most often clinically
employed, with the laboratory providing the assay typically providing recommendations
regarding ideal target blood drug levels.
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Therapeutic Drug Monitoring
Because gastrointestinal absorption is variable in patients receiving cyclosporine,
monitoring blood concentrations to ensure therapeutic dosing is often recommended.
However, there are only a limited number of clinical studies in veterinary medicine which
address target therapeutic cyclosporine blood concentrations. Pharmacokinetic studies
demonstrate a wide variability in cyclosporine pharmacokinetics, with differing blood
levels in dogs administered the same oral dosage (14, 37-39). Monitoring blood levels is
a way to attempt to optimize the dose for individual patients. Current recommendations
evolved from initial work with organ transplantation in dogs (40-41). Initial
recommendations for immunosuppression centered on achieving a minimum target
trough blood drug concentration of 500 ng/ml, with blood collected just before the next
oral dose (6).
While human medicine initially utilized measurement of trough concentrations,
laboratories have since changed to using peak concentrations as well as
pharmacodynamic monitoring. Trough concentrations did not adequately predict
sufficient immunosuppression, and clinical outcomes were not acceptable (3). Drug
concentrations at which nephrotoxicity and hepatotoxicity occurred were identified using
trough levels, but not the ideal levels to induce and maintain immunosuppression.
Further work identified that the concentration measurement of the area under the curve
(AUC) for hours 0-12 in the dosing interval provided a much more reliable and
successful indicator of clinical immunosuppression, with patient outcome significantly
improving. To calculate the AUC for hours 0 to 12, multiple blood samples had to be
collected. Based on the idea that absorption of the Neoral® preparation is more rapid and
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complete during the first four hours after dosing, the AUC for hours 0 to 4 were
investigated as a simpler alternative to the AUC 0 to 12 hours. There was a close
correlation between the two methods, with fewer samples needed for the AUC for 0 to 4
hours. Further work in human medicine identified that the peak drug concentration, or
the concentration in plasma 2 hours post-dosing, approximated the patient outcome and
success as that seen when using the concentration measurement of the area under the
curve for hours 0-4, while trough levels correlated poorly with the area under the curve
for hours 0-4. These findings apply to the Neoral® formulation, as the peak blood
concentration reliably occurs between 1 and 2 hours, and the 2 hour peak captures
virtually all patients. In contrast, these findings cannot be applied to the Sandimmune®
formulation, as the peak measurement varies between 2 and 6 hours, nor for generic
versions of Neoral®, as testing has not validated the peak measurement and studies have
shown decreased efficacy with generic formulations compared to the Neoral®
formulation. With the peak measurement only requiring a single blood collection, it has
now become the single best blood concentration measurement for use during organ
transplantation when monitoring cyclosporine pharmacokinetics using the Neoral®
formulation.
In veterinary medicine, measurement of trough cyclosporine concentrations
prevailed for many years based on initial work done in renal transplant studies. Current
recommendations from laboratories offering therapeutic drug monitoring in dogs
receiving cyclosporine therapy typically involve the evaluation of both peak and trough
levels. Exact recommendations depend on the laboratory reference ranges as well as the
assay used to measure cyclosporine concentrations.
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Pharmacodynamics
Pharmacokinetic studies provide evidence that cyclosporine blood concentrations
in patients are within the estimated target therapeutic range recommended by referral
laboratories. For some patients, this estimation may accurately predict
immunosuppression, while for others, there may not be clinical efficacy despite achieving
a target therapeutic range of blood cyclosporine concentrations, or there may be adverse
side effects. This variability in response to comparable blood concentrations may be
attributed to individual pharmacological responses to cyclosporine between patients. A
wide variability in the relationship between clinical efficacy and ‘therapeutic’ drug
concentrations is seen in clinical practice (42). For this reason, several
pharmacodynamic assays have now been developed in human medicine in an attempt to
better estimate the amount of cyclosporine needed for the treatment of disease and
prevention of organ rejection in transplant patients as well as to minimize side effects.
Pharmacodynamic assays investigate a drug’s effect on target cells. Several
pharmacodynamic biomarkers of immunosuppression have been studied in human
medicine, including lymphocyte proliferation, enzyme activity (calcineurin), lymphocyte
surface antigens, and intracellular cytokine quantification. Through pharmacodynamic
monitoring, human studies have shown individually distinct degrees of calcineurin
inhibitor sensitivity in patients. Pharmacodynamic monitoring shows great promise for
optimizing cyclosporine therapy as well as delivering individualized therapy.
Few such pharmacodynamic studies are found in the veterinary literature. One
study demonstrated suppression of lymphocyte proliferation via flow cytometry after the
use of topical cyclosporine for the treatment of keratoconjunctivitis sicca in dogs. In
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dogs treated with 2 percent topical ocular cyclosporine, there was decreased lymphocyte
proliferation by one month and a statistically significant reduction at three months (43).
In more recent veterinary studies utilizing cytokine analysis, quantitative reverse
transcriptase polymerase chain reaction (QRT-PCR) assays are being used to measure
cellular messenger ribonucleic acid (mRNA) expression. One recent study investigated
the effects of cyclosporine on activated canine mononuclear cells in vitro, and
demonstrated a concentration-dependent reduction in IL-2, IL-4, and IFN-γ mRNA
expression via QRT-PCR (44). Another recent study evaluated cellular IL-2 and IFN-γ
mRNA expression within lesional biopsies from German shepherd dogs with anal
furunculosis before and after therapy with oral Atopica® for 4 weeks duration, and
showed an initial significant increase in cytokine mRNA expression in diseased tissue as
compared to control tissues. Diseased tissues which were evaluated post-treatment with
cyclosporine demonstrated a significant reduction in IL-2 expression, and a lesser
decrease in IFN-γ mRNA expression. A correlation was not found between posttreatment T-cell cytokine mRNA expression and the severity of disease in dogs with
residual disease (45). There is clearly a need to develop and investigate
pharmacodynamic assays that have the potential to more accurately predict the
immunosuppressive effects of cyclosporine in the individual patient, and that allow dose
adjustments that improve clinical outcomes.
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CHAPTER III
PHARMACODYNAMIC MONITORING OF CANINE T-CELL CYTOKINE
RESPONSES TO ORAL CYCLOSPORINE
Introduction
Cyclosporine is a potent immunosuppressive drug with treatment applications in
both human and veterinary medicine. Cyclosporine specifically targets T-cell function,
ultimately inhibiting calcineurin within the cell (1-4).
Inhibition of calcineurin prevents activation of nuclear factor of activated T-cells,
which regulates the production of several important cytokines including interleukin-2
(IL-2), interleukin-4 (IL-4), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha
(TNF-α) (5,6). Decreased production of IL-2 is thought to be the main cause of the
cyclosporine’s immunosuppressive effects (7-9).
Cyclosporine has been used to treat many inflammatory and immune-mediated
diseases in the dog (4,10-17). The lipophilic nature of cyclosporine affects drug
bioavailability, which has made the use of the drug challenging to clinicians. The oral
bioavailability of cyclosporine is highly unpredictable, with wide ranges of blood
concentrations seen in dogs receiving similar dosages (13,14,18-20). Because of this
variability, therapeutic drug monitoring of cyclosporine blood concentrations is usually
This article is published in the Journal of Veterinary Internal Medicine. Archer TM,
Fellman CL, et al. Pharmacodynamic Monitoring of Canine T-Cell Cytokine Responses
to Oral Cyclosporine. J Vet Intern Med 2011; 25: 1391-1397.
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recommended if a favorable response is not initially achieved (3,20,21). Interpretation of
cyclosporine blood concentrations in the individual dog, however, is difficult. There is
limited evidence in the veterinary literature correlating cyclosporine blood concentrations
with clinical response for many inflammatory and immune-mediated diseases. Target
therapeutic ranges are often anecdotal, and recommendations vary considerably among
references with regards to desired blood cyclosporine concentrations (20,22,23). Clinical
response is often the most reliable means of assessing immunosuppression in treated
animals. The relationship between clinical response and drug blood concentrations also
appears to be highly variable, with a given cyclosporine concentration being effective in
some animals but not others (13,24). Additionally, for some conditions, positive clinical
response is often apparent at drug concentrations well below those typically
recommended for immunosuppression (19). For this reason, while cyclosporine is
marketed for the treatment of canine atopic dermatitis, therapeutic drug monitoring is not
routinely recommended for this condition (10,25,26). Based on the unpredictable
relationship between blood drug concentrations and clinical response, there is clearly a
need to find a better method for monitoring the immunosuppressive effects of
cyclosporine, particularly in animals with life-threatening conditions.
Pharmacodynamic assays evaluating selected biomarkers within the immune
system are advocated in human medicine to help determine drug efficacy and make
dosing recommendations (27). For cyclosporine, these assays include quantification of
drug target enzymes (calcineurin), cytokines (IL-2 and IFN-γ), and markers of
lymphocyte proliferation or activation (CD25 and CD95) (28-32). These biomarkers are
involved in normal and pathological immune responses, so their inhibition serves as a
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quantitative, objective surrogate for inhibition of immune function. Pharmacodynamic
monitoring of biomarkers of immunosuppression offers a more individualized approach
to immunosuppressive therapy when blood concentrations do not correlate well with
clinical response in dogs.
Pharmacodynamic monitoring of biomarkers such as cytokines that are indicative
of immunosuppression has yet to be thoroughly explored in the dog. Our study uses flow
cytometry to assess the effects of cyclosporine on canine T-cell production of three
cytokines, IL-2, IL-4, and IFN-γ, that have potential utility as biomarkers of
immunosuppression. These cytokines were evaluated at two drug dosages: a high dosage
adjusted to attain trough blood concentrations that are expected to be reliably
immunosuppressive, and the much lower dosage used to treat atopic dermatitis.
Materials and Methods
Dogs
Seven healthy intact female Walker hounds were used for the project. Health
screening was performed prior to the study and included physical examination, complete
blood count, serum biochemistry profile, urinalysis, fecal flotation, and heartworm
testing. All animals were cared for according to guidelines approved by the Mississippi
State University Institutional Animal Care and Use Committee. The animal facilities and
program at Mississippi State University are accredited by the American Association for
Accreditation of Laboratory Animal Care.
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Study Design
Blood was drawn for baseline flow cytometric measurement of T-cell expression
of the cytokines IL-2, IL-4, and IFN-γ in all dogs. Baseline samples were assessed in
duplicate and averaged. Dogs were then given two different dosages of cyclosporine, a
high dosage and then, 14 days after completion of the high dosage study, a much lower
dosage. For the high dosage study, microemulsified cyclosporinea was administered at a
starting oral dosage of 10 mg/kg every 12 hours. Dosages were adjusted to achieve a
trough blood cyclosporine concentration (measured 12 hours after dosing) of at least 600
ng/mL, a trough concentration that has previously been established to attain sufficient
immunosuppression to prevent organ rejection in canine transplant recipients (23, 24, 33).
One dog attained this trough concentration at the initial starting dosage, while the other
six required dosage increases. On day 8 of cyclosporine administration, after trough
drug concentrations of at least 600 ng/mL had been confirmed in all dogs, blood was
drawn eight hours after dosing and processed for repeat cytokine measurement. This
time point was optimized in an earlier unpublished pilot study. Any cytokine not shown
to be suppressed by high dosage cyclosporine was not subsequently analyzed in the low
dosage cyclosporine phase of testing. Cyclosporine was then discontinued and, after a
two week washout period, cytokine expression was again measured to ensure return to
baseline levels before commencing the subsequent low dosage study. For the low dosage
study, cyclosporine was administered at the labeled dosage for atopic dermatitis (5 mg/kg
orally every 24 hours), and cytokine levels were again measured on day 8 of drug
administration. Trough cyclosporine blood concentrations (measured at hour 24,
immediately prior to the next dosage) were also measured by HPLC on day 8.
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Cytokine Analysis
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized
blood samples collected from each dog utilizing density gradient centrifugation with
Histopaque®-1077b, similar to a previously described method (34). The isolated PBMC
were reconstituted in complete media with an equal volume to that of the original blood
sample in order to approximate the cell density present for each dog. RPMI 1640
mediumc supplemented with 10% heat-inactivated fetal bovine serumd, GlutaMAXe, 1
mM sodium pyruvatef, 55 µM 2-mercaptoethanolg, 75 μg/mL gentamicinh, 2 mM
HEPES, and 1 μL/mL MEM Amino Acids Solution without L-glutaminei was used for
cell culture.
Cytokine expression levels in peripheral blood T-cells were analyzed as described
previously (35). Briefly, half of the isolated PBMC were activated with 12.5 ng/mL
phorbol-12-myristate-13-acetatej and 0.8 μM ionomycink, and the other half remained
untreated. All cells were then incubated for 12 hours at 37°C in a 5% CO2 incubator.
Brefeldin A at a concentration of 1 μg/mL was added to each well with two hours
remaining in the incubation to stop cytokine secretion from T-cells. Cells were then
collected and washed with phosphate buffered saline. All samples were incubated with a
fluorescein isothiocyanate-conjugated anti-CD3 monoclonal antibodyl for 30 minutes at
room temperature in the dark, and fixed and permeabilized using the BD
Cytofix/Cytoperm Plus Kitm following the manufacturer’s instructions. Cells were then
incubated with appropriate antibodies for labeling of the cytokines of interest, either Rphycoerythrin-conjugated anti-bovine IL-4n (cross-reactive with canine IL-4 (36)), Rphycoerythrin-conjugated anti-bovine IFN-γo (cross-reactive with canine IFN-γ (36)), or
40

biotinylated anti-canine IL-2p, for 30 minutes at room temperature in the dark. The anticanine IL-2 antibody has been shown to be canine specific by in-house testing performed
by the manufacturer. IL-2 samples had an additional 20 minute incubation with Rphycoerythrin-conjugated streptavidinq at room temperature in the dark. A final wash
was applied to these samples, and all cells were then resuspended in phosphate buffered
saline with 0.2% bovine serum albumin.
Cell staining was evaluated using a BD FACSCalibur Flow Cytometer and
analyzed with CellQuest Pro softwarer. Forward scatter and side scatter were used to
identify and gate lymphocytes based on their size and granularity. A second gate selected
CD3-positive cells. Cytokine levels were measured from cells that were located in both
gates, and 10,000 total events per sample were collected. Mean fluorescence intensity
(MFI) values with single histogram statistics were used for assessment of cell staining.
Negative controls included unactivated samples and isotype controls.
Cyclosporine Blood Concentrations
Blood cyclosporine concentrations were measured via HPLC, with the trough
concentration taken 12 hours (high dose phase) or 24 hours (low dose phase) after the
previous oral dose. Blood was collected into EDTA anticoagulant tubes, and analyzed
within 24 hours using a modification of the HPLC assay used for therapeutic drug
monitoring at the University of California at Davis (John D Patz, personal
communication, 2008). Standard curves were made using blank EDTA anticoagulated
whole blood and cyclosporines at 0, 200, 400, 800, and 1600 ng/mL. The extraction
procedure used 2 mL of whole blood sample mixed with 6 mL of a protein precipitating
solution consisting of 5% zinc sulfate, 20% acetonitrile, 30% methanol, and water. This
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solution also contained 400 ng/mL of cyclosporine Dt as an internal standard. After
vortexing and subsequent centrifugation, the supernatant was added to a prepared C18
solid phase extraction columnu. After filtration of the sample by vacuum, the solid phase
extraction column was washed with 5 mL of 50% acetonitrile followed by 1 mL of 100%
methanol for elution of the drug. To the methanol eluent 200 μL of water was first added
followed by 300 μL of hexane. This fluid was then vortexed and centrifuged with 200 μL
of the aqueous layer extracted and placed in vials for subsequent HPLC analysis using a
sample injection volume of 100 μL.
An 1100 HPLC systemv with degasser, quaternary pump, autoinjector, and diode
array detector was used. The reverse phase column was a Phenomenex Luna 5u C18(2)
with guard cartridge. The column was maintained at 75 degrees C. A gradient mobile
phase at 1 mL per minute was used consisting of acetonitrile (A) and water adjusted to
pH 3.1 (B). The gradient was initially 65% A and 35% B that transitioned linearly over 5
minutes to 70% A and 30% B. This ratio was then held for 15 minutes. A 5 minute reequilibration time followed each injection. Detection was at 200 nm. The retention time
for cyclosporine was 4.2 min versus 5.6 minutes for cyclosporine D. The assay was
linear over the standard curve range of 200 to 1600 ng/mL with an r2 of 0.9889. Based
on the method described by Taylor, the limit of quantification (LOQ) was 189.93 ng/ml
and the limit of detection (LOD) was 56.97 ng/ml (37). The assay had an average
coefficient of variation of 6.7% (range 3.7 to 9.9%) and an average accuracy of 94.4%
(range 92 to 98%).
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Statistical Analysis
A paired comparison design was used in this study. The Wilcoxon signed rank
test was used to compare the average baseline cytokine MFI values to the MFI values
after treatment for each cytokine at the high dosage. The Wilcoxon signed rank test was
also utilized to compare the average baseline cytokine MFI values to the MFI values after
treatment for IL-2 and IFN-γ at the low dosage, to compare the washout cytokine MFI
values to the MFI values after treatment for IL-2 and IFN-γ at the low dosage, and to
compare the baseline cytokine MFI values to the washout cytokine MFI values for IL-2
and IFN-γ. Analyses were conducted for both cyclosporine dosages for IL-2 and INF-γ
while only the effect of high dosage cyclosporine was analyzed for IL-4. The
UNIVARIATE procedure in SAS for Windows® version 9.2w was used for statistical
analysis. P-values ≤ 0.05 were considered significant.
The data was analyzed to determine if MFI and cyclosporine concentration were
correlated using PROC CORR (SAS for Windows® version 9.2w). A separate analysis
was conducted for each cyclosporine dosage and cytokine combination.
Results
Cytokine Analysis
Expression of both IL-2 and IFN-γ decreased significantly from baseline values
following administration of high dosage cyclosporine (P for IL-2= 0.0156, P for IFN-γ=
0.0156), and cytokine expression decreased in all 7 dogs for both cytokines (Table 1). In
contrast, IL-4 expression following administration of high dosage cyclosporine varied
markedly between individual dogs, with no significant difference between baseline
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values and values after treatment (P-value of 0.2188). Due to the inconsistent and nonsignificant changes in T-cell IL-4 expression in dogs administered cyclosporine at a high
dosage, this cytokine was not evaluated in the subsequent low dose trial.
Expression of IFN-γ decreased significantly from baseline values (P= 0.0156) as
well as washout values (P= 0.0156) following administration of low dosage cyclosporine,
and cytokine expression decreased in all 7 dogs (Table 2). There was not a significant
difference between the IFN-γ baseline values and the IFN-γ washout values (P= 0.9375).
Expression of IL-2 at the low cyclosporine dosage had more variability in individual dogs
compared to expression of IFN-γ at the same dosage, and compared to expression of IL-2
at the high cyclosporine dosage, with only 5 of 7 dogs showing moderately suppressed
IL-2 expression on the lower dosage. Expression of IL-2 following administration of low
dosage cyclosporine was not significantly different from baseline values (P= 0.1094) nor
from washout values (P= 0.6875). IL-2 washout values were found to be significantly
lower than the baseline IL-2 values (P= 0.0469).
Cyclosporine Blood Concentrations
The high cyclosporine dosage consisted of a starting dosage of 10 mg/kg every 12
hours, with the 12 hour doses adjusted upwards as needed to ensure trough blood drug
concentrations of at least 600 ng/mL. One dog achieved the minimum target trough
concentration on the starting dose, while the other 6 dogs needed doses titrated up and
had confirmed cyclosporine trough concentrations above 600 ng/mL by day 8. The low
cyclosporine dosage was 5 mg/kg every 24 hours. After 8 days of dosing at the low
cyclosporine dosage, blood was drawn for measurement of trough concentrations. Each
trough concentration was drawn just prior to administration of the next cyclosporine
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dosage. Trough blood cyclosporine concentrations for high dosage cyclosporine ranged
from 728 ng/mL to 1330 ng/mL, with a median value of 1005 ng/mL (Table 1). Trough
blood cyclosporine concentrations for low dosage cyclosporine ranged from below the
level of detection (57 ng/mL) to 145 ng/mL, with all values being below the limit of
quantification (190 ng/mL) (Table 2).
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Flow cytometric measurement of activated T-cell expression of interleukin-2 (IL-2) and interferon-gamma (IFN-γ) before
(baseline), after washout, and after day 8 administration of low dosage oral cyclosporine. Accompanying trough blood
cyclosporine concentrations during the administration of low dosage cyclosporine are shown.

Table 2

Flow cytometric measurement of activated T-cell expression of interleukin-2 (IL-2), IL-4, and interferon-gamma (IFN-γ)
before (baseline) and after (day 8) administration of high dosage oral cyclosporine. Accompanying trough
blood cyclosporine concentrations during the administration of high dosage cyclosporine are shown.

Table 1

Cyclosporine Blood Concentration and Cytokine Correlation
IL-2 MFI was not significantly correlated with cyclosporine concentration for
either high dosage (r=-0.16, p=0.7317) or low dosage (r=-0.22, p=0.6293) cyclosporine
administration. Similarly, IFN-γ MFI was not significantly correlated with cyclosporine
concentration for either high dosage (r=-0.41, p=0.3619) or low dosage (r=-0.13,
p=0.7858) cyclosporine administration.
Discussion
Our study has established that activated T-cell expression of two cytokines, IL-2
and IFN-γ, is reliably suppressed in dogs receiving cyclosporine at established
immunosuppressive dosages, and that these cytokines are therefore strong candidates for
development as biomarkers of immunosuppression for subsequent pharmacodynamic
assays. There is clearly a need to develop assays that have the potential to more
accurately predict the immunosuppressive effects of cyclosporine in the individual dog,
and that allow dosage adjustments that improve clinical outcomes. Such assays have the
potential to provide individualized therapy in dogs suffering from severe and lifethreatening immune mediated diseases, as blood concentrations do not always correspond
to clinical response (19).
Our study utilized flow cytometry to evaluate T-cell expression of cytokines to
quantitate the biological effects of cyclosporine on T-cells in healthy dogs. Many human
studies include flow cytometric analysis of T-cell cytokine and surface molecule
expression as biomarkers when investigating the immunosuppressive effects of drugs
such as cyclosporine (28, 38–40). Few such studies are found in the veterinary literature,
though one study did demonstrate suppression of lymphocyte proliferation via flow
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cytometry after the use of topical cyclosporine for the treatment of keratoconjunctivitis
sicca in dogs (41). Cytokine analysis in veterinary immunosuppression research more
commonly utilizes quantitative reverse transcriptase polymerase chain reaction (QRTPCR) assays to measure cellular messenger ribonucleic acid (mRNA) expression (42-46).
One recent study investigating the effects of cyclosporine on canine mononuclear cells in
vitro, for example, showed a concentration-dependent reduction in IL-2, IL-4, and IFN-γ
mRNA expression via QRT-PCR (43). Another recent study evaluated cellular IL-2 and
IFN-γ mRNA expression within lesional biopsies from German shepherd dogs with anal
furunculosis before and after therapy with cyclosporine, and demonstrated a significant
reduction in IL-2 expression after treatment (42). Previous in vitro work in our
laboratory established the utility of flow cytometric techniques for monitoring the effects
of cyclosporine on activated T-cell expression of cytokines and surface molecules (35),
and we therefore elected to use this method for our current study. This study has
established that activated T-cell expression of the cytokines IL-2 and IFN-γ shows
promise as a potential biomarker of immunosuppression for pharmacodynamic
monitoring.
Although activated T-cell expression of IL-2 and IFN-γ was reliably suppressed
by high dosage cyclosporine therapy in the dogs in our study, expression of IL-4 was not
similarly affected. We included IL-4 in our high dosage study because previous work in
our laboratory showed that activated T-cell expression of IL-4 was suppressed by in vitro
exposure to cyclosporine (35), and because IL-4 was used in human studies as a
biomarker of immunosuppression (28). Because IL-4 did not reliably suppress during the
high dosage cyclosporine phase of our current study, we concluded that further
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exploration of IL-4 as a potential biomarker was not warranted, and elected not to include
this cytokine in the low dosage phase of our study. Failure of T-cell expression of IL-4 to
suppress after administration of oral cyclosporine may be due to a dog-specific difference
in in vivo responses compared to in vitro responses. One in vivo study of cyclosporine in
dogs showed a drug-associated reduction in IL-2 but not in antibody (IgA, IgG, and IgM)
production, a presumed Type 2 helper T-cell-dependent response which utilizes IL-4 for
up-regulation (47). Although the researchers did not directly measure IL-4, they
concluded that cyclosporine had a negligible effect on humoral immunity (47).
In our study, we used two extremes of cyclosporine dosing, a high dosage
adjusted upwards as needed to meet target trough blood concentrations of 600 ng/mL,
and a much lower fixed dosage. We elected to use our high dosage protocol in order to
be as certain as possible that the treated dogs were reliably immunosuppressed, and
thereby establish the degree of suppression of cytokine biomarkers associated with
immunosuppression. With the high dosage protocol, activated T-cell expression of IL-2
and INF-γ was significantly reduced, consistent with findings in pharmacodynamic
studies in people (28, 29, 48). The lower fixed cyclosporine dosage utilized in our study
is the labeled dosage approved by the United States Food and Drug Administration for
the treatment of canine atopy (24). The atopy dosage of cyclosporine has not been
previously definitively documented to cause significant suppression of the canine
immune system, and whether or not this low dosage of cyclosporine can cause clinically
relevant immunosuppression remains controversial among veterinary dermatologists.
Individual dogs on the atopy dosage of cyclosporine long term have however been
anecdotally reported to develop secondary infections, suggesting the possibility that even
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this low dosage can sometimes cause immunosuppression. Our study provides
preliminary supportive evidence that low dosages of cyclosporine may have
immunosuppressive effects in dogs, in that even the atopy dose used in our low dose
phase was associated with a significant decrease in activated T-cell expression of IFN-γ.
Remarkably, T-cell expression of both IFN-γ and IL-2 was observed to decrease in
individual dogs even when trough blood cyclosporine concentrations were far below
published target trough concentrations and were below the limit of quantification, and in
two instances, below the level of detection by HPLC. That some dogs showed substantial
decreases in T-cell cytokine production despite having extremely low trough drug
concentrations suggests that therapeutic drug monitoring of trough blood cyclosporine
concentrations as a means of predicting immunosuppression in individual dogs is of
questionable reliability. Our low dosage study demonstrated that blood drug
concentrations and T-cell suppression were both highly variable among individual dogs
treated with the same oral dosage of cyclosporine, supporting the proposition that, in a
clinical setting, pharmacodynamic assays may be needed in order to determine individual
patient responses to immunosuppressive therapy. Comparison of the cyclosporine
concentrations and MFI values for each cytokine did not demonstrate a correlation
between the two measures at either dosage. This further calls into question the utility of
blood drug concentrations and supports the need for a more individualized, patient
specific approach when monitoring cyclosporine therapy in dogs.
One weakness of our study is that, because of the lack of a cross-over design, all
dogs received high cyclosporine dosages before subsequently receiving low dosages. A
possible residual drug effect following high dosage cyclosporine could have played a role
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in our IL-2 analysis because a statistically significant reduction in values was seen
between original baseline and washout values. This effect was not appreciated with the
analysis of the IFN-γ data, a difference that could be due to a possible prolonged posttreatment effect of cyclosporine on the expression of IL-2 but not IFN-γ.
Our study was performed in healthy research dogs, with demonstration of
suppression of T-cell expression of cytokines in response to oral dosing of cyclosporine.
Clinical dosing recommendations cannot be made at this time based on our assay, since
we do not as yet know whether cytokine expression corresponds with clinical efficacy in
dogs as it does in humans. Our study only incorporated two extreme dosages of
cyclosporine, and did not evaluate alterations in activated T-cell expression of cytokines
associated with the mid-range cyclosporine dosages that are often used for treating
inflammatory and immune-mediated diseases in the dog. Performing similar analyses at
cyclosporine dosages between the two dosages used in our study would further clarify the
potential clinical utility of flow cytometric measurement of T-cell cytokine expression as
a biomarker of immunosuppression. Finally, clinical studies in clinical patients at
dosages approximating those typically used for immunosuppressive therapy will help
determine this assay’s ability to predict immunosuppression and allow for dose
adjustments in the individual dog.
Endnotes
a

Atopica, Novartis Animal Health, Basel, Switzerland

b

Histopaque®-1077, Sigma Aldrich, St. Louis, MO

c

RPMI 1640 Medium, 21870-084, Invitrogen, Carlsbad, CA

d

10% Heat-inactivated fetal bovine serum, 10438-026, Invitrogen, Carlsbad, CA
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e

GlutaMAX, 35050, Invitrogen, Carlsbad, CA

f

Sodium Pyruvate, 11360, Invitrogen, Carlsbad, CA

g

2-mercaptoethanol, 21985-023, Invitrogen, Carlsbad, CA

h

Gentamicin, 15750-060, Invitrogen, Carlsbad, CA

i

MEM Amino Acids Solution without L-glutamine, 11130, Invitrogen, Carlsbad, CA

j

Phorbol-12-myristate-13-acetate, P-8139, Sigma Aldrich, St. Louis, MO

k

Ionomycin, I-0634, Sigma Aldrich, St. Louis, MO

l

Anti-canine CD3 antibody, MCA1774F, AbD Serotec, Raleigh, NC

m

BD Cytofix/Cytoperm Plus Kit, Becton Dickinson, San Jose, CA

n

Anti-bovine IL-4 antibody, MCA1820PE, AbD Serotec, Raleigh, NC

o

Anti-bovine IFN-γ antibody, MCA1783PE, AbD Serotec, Raleigh, NC

p

Biotinylated anti-canine IL-2, BAF1815, R&D Systems, Minneapolis, MN

q

Streptavidin, #60669, Anaspec, San Jose, CA

r

FACSCalibur Flow Cytometer and CellQuest Pro software, Becton Dickinson, San Jose,
CA
s

Cyclosporine, Sigma-Aldrich, St. Louis, MO USA

t

Cyclosporine D, Novartis Pharmaceuticals, East Hanover, NJ USA

u

Varian Bond Elut 1 cc 100mg solid phase extraction column, Varian Incorporated,
Walnut Creek, CA USA
v

Agilent 1100 HPLC system, Agilent Technologies, Santa Clara, CA USA

w

SAS for Windows® version 9.2, SAS Institute Inc., Cary, NC
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CHAPTER IV
CONCLUSION
Our preliminary work and in vivo study documented measurable suppression of
selected biomarkers of immunosuppression in T-cells, more specifically the cytokines IL2 and INF-γ, when T-cells were exposed to cyclosporine. The in vivo study documented
that high doses of cyclosporine reliably suppressed T-cell expression of both IL-2 and
IFN-γ, with suppression of IFN-γ even at the much lower cyclosporine dosage commonly
used for atopic dermatitis. During the in vivo study, measurable suppression of T-cell
cytokine expression was noted to occur even at very low trough blood cyclosporine
concentrations that were well below the target immunosuppressive ranges recommended
by most reference laboratories, calling into question the ability of pharmacokinetic assays
to be the sole technique for assessing the efficacy of cyclosporine therapy. Therapeutic
drug monitoring may not necessarily be able to predict the pharmacological effects of the
drug on the immune system. There is clearly the need to develop pharmacodynamic
assays which can assess the effects of cyclosporine on the immune system during therapy
and allow for more accurate dose adjustments to improve clinical outcome.
Although cyclosporine is gaining favor for treating a wide and increasing
number of inflammatory and immune-mediated diseases in veterinary medicine, optimal
oral dosing protocols in dogs are still unclear. For many dermatologic and mild
gastrointestinal disorders, cyclosporine is often used at the lowest effective dose that
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allows continued resolution of clinical signs, without the need for measurement of blood
drug concentrations. Even at the low atopic dose traditionally not thought to induce
immunosuppression, some dogs in our study showed clear suppression of biomarker
expression. This phenomenon occurred at very low trough cyclosporine concentrations.
Explanations for this effect are most likely multifactorial. In human medicine, peak
cyclosporine concentrations have been shown to be consistently a better predictor of both
the area under the curve and immunosuppressive efficacy compared to trough levels.
Also, pharmacodynamic monitoring in human medicine has shown individual-toindividual variability in calcineurin inhibition in response to comparable blood
concentrations of cyclosporine, demonstrating individual sensitivity to the effects of the
drug. Our findings provide evidence supporting the concept of individual drug
sensitivities. Veterinary dermatologists have debated for years about whether the low
atopy dose of cyclosporine could explain secondary infections sometimes seen in dogs
treated with cyclosporine for atopy. Our findings strongly suggest that the immune
system in some dogs on the low atopy dose of cyclosporine can still be significantly
affected, potentially leading to clinically relevant immunosuppression. Clinically, a
pharmacodynamic assay such as ours could help to individually adjust cyclosporine
dosages, and to explore sensitivity to cyclosporine as a potential cause in those patients
being treated for canine atopy that appear to develop immunosuppression secondary to
treatment.
With more severe and immediately life-threatening immune-mediated diseases,
it is currently recommended that cyclosporine dosages be adjusted based on the
monitoring of blood cyclosporine concentrations. Typically, trough blood concentrations
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are used to adjust drug dosages, but recommendations vary widely depending on the
disease treated and on the assay utilized to measure drug concentrations. Monitoring
cyclosporine blood concentrations is recommended in patients with severe diseases
because, in the individual patient, cyclosporine pharmacokinetics are inherently highly
variable and unpredictable, largely due to issues with oral bioavailability. However, even
if therapeutic drug monitoring is used to adjust therapy, patients with comparable drug
blood levels may have quite different outcomes, as blood levels do not always correspond
to clinical response. This may lead us to question whether cyclosporine blood
concentrations should be measured at all. We generally can reasonably estimate starting
immunosuppressive cyclosporine dosages for the treatment of immune-mediated blood
disorders. If there is a good clinical response, blood concentrations are generally not
measured, and therapy is tapered very slowly over time in a controlled fashion. When a
good clinical response is not achieved, measurement of blood concentrations may not
help with adjustment of therapy, as some dogs on very low doses of cyclosporine, with
low trough concentrations, still have measurable T-cell cytokine suppression. With
further investigation focusing on peak cyclosporine concentrations, target concentrations
may be identified which better predict adequate immunosuppression and ascertain ranges
which put patients at risk for toxicity.
In human medicine, studies have shown patient-to-patient variability in the effects
of cyclosporine on immune function even when there are comparable blood cyclosporine
levels, demonstrating the need for a better assay for assessing the immune system during
cyclosporine therapy. Pharmacodynamic monitoring in conjunction with
pharmacokinetic monitoring is being investigated in human medicine as a means to
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provide a better overall assessment of immunosuppression and predictor of clinical
outcome in response to cyclosporine therapy. Our research has developed a
pharmacodynamic assay that utilizes cytokines as biomarkers of immunosuppression to
quantitate the biological effects of cyclosporine on T-cells in healthy dogs.

The

developed pharmacodynamic assay would be relevant for assessing and monitoring the
immune system during therapy with any medication which down-regulates IL-2 and INFγ cytokine production. This would include drugs which target any part of the cascade
from the cell surface signal all the way down into the nucleus for gene expression. Most
notably are those medications targeting calcineurin with subsequent down-regulation of
nuclear factors of activation of T-cells (NFAT), leading to decreased cytokine gene
expression. Beyond cyclosporine, medications for which our pharmacodynamic assays
might be applicable include glucocorticoids and tacrolimus. Our assay may not be
directly applicable to assessing disease-induced immunosuppression, as often this is due
to decreased populations of white blood cells allowing secondary infection to occur,
rather than decreased T-cell function.
Our study utilized flow cytometry to evaluate T-cell expression of cytokines.
Flow cytometry, which requires rapid and specialized sample processing, may not
however be the ideal tool the pharmacodynamic monitoring of clinical patients, and a
quantitative real-time PCR (QRT-PCR) assay may in the long term hold more promise as
a method for clinical pharmacodynamic monitoring of patients. Our study has
established that, regardless of the method eventually developed for clinical use, activated
T-cell expression of the cytokines IL-2 and IFN-γ shows promise as a potential
biomarker of immunosuppression for pharmacodynamic monitoring of cyclosporine.
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Human studies have investigated a number of differing measures of the immune
system to assess the pharmacodynamic effects during cyclosporine therapy. We chose
our biomarkers of immunosuppression based on previous human studies and the
availability of antibodies which were canine specific or cross reactive to dogs.
Calcineurin activity is an assay used commonly in human studies, directly assessing the
effects of cyclosporine in its cellular target. In our initial investigation towards
pharmacodynamic monitoring, measurement of calcineurin activity was not widely used,
and procedures such as flow cytometry were more readily utilized. In the process of
developing a clinical assay, the time and manpower needed to process samples has to be
considered. Quantifying calcineurin activity could be an alternative assay to measure the
pharmacodynamic effects of cyclosporine on canine T-cells. This assay has never been
published in dogs, and would have to be thoroughly investigated before potential
development as a viable canine specific assay. In contrast, our ability to quantify changes
in IL-2 and IFN-γ expression when T-cells are exposed to cyclosporine both in vitro as
well as in vivo has already been established as repeatable, and appears to be a valid and
viable assay for further development in the clinical monitoring of patients.
Our in vivo study only incorporated two extreme doses of cyclosporine, and did
not evaluate activated T-cell expression of cytokines at dosages which are often
employed for treating inflammatory and immune-mediated diseases in the dog.
Performing similar analyses at cyclosporine dosages between the two extreme dosages
used in our study would further clarify the potential clinical utility of flow cytometric
measurement of T-cell cytokine expression as a biomarker of immunosuppression.
Additionally, comparison of flow cytometry versus QRT-PCR as a means of monitoring
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T-cell cytokine expression in dogs receiving cyclosporine may help identify which
method is likely to be of more value for clinical pharmacodynamic monitoring. Finally,
clinical trials in canine patients with naturally-occurring disease will be needed to
establish the clinical utility of adjusting therapy based on measurement of potential
biomarkers of immunosuppression, both with cyclosporine and eventually with other
immunosuppressive agents that affect T-cell function. With further investigation into the
pharmacokinetics and pharmacodynamics of cyclosporine in veterinary medicine, a better
assessment of the immune status may be gained when combining these two techniques
and allow for optimization of therapy and delivery of individualized treatment.
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